We are live on
!
Find out more
LPC
Lion Point Capital Portfolio holdings
AUM
$16.7M
1-Year Est. Return
119.35%
This Fund
S&P 500
This Quarter
Est. Return
+34.99%
1 Year Est. Return
+119.35%
3 Year Est. Return
+204.43%
5 Year Est. Return
+220.32%
10 Year Est. Return
+1,396.08%
AUM
$17.6M
AUM Growth
+$2.87M
(+20%)
Cap. Flow
+$1.84M
Cap. Flow
% of AUM
10.47%
Top 10 Holdings %
Top 10 Hldgs %
58.11%
Holding
27
New
8
Increased
3
Reduced
8
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MoonLake Immunotherapeutics
MLTX
|
+$3.52M |
| 2 |
Royalty Pharma
RPRX
|
+$775K |
| 3 |
Jasper Therapeutics
JSPR
|
+$764K |
| 4 |
Kura Oncology
KURA
|
+$328K |
| 5 |
DAWN
Day One Biopharmaceuticals
DAWN
|
+$289K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ardelyx
ARDX
|
+$938K |
| 2 |
Mineralys Therapeutics
MLYS
|
+$865K |
| 3 |
Kiniksa Pharmaceuticals
KNSA
|
+$731K |
| 4 |
Fennec Pharmaceuticals
FENC
|
+$629K |
| 5 |
BridgeBio Pharma
BBIO
|
+$619K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Mineralys Therapeutics
MLYS
$2.41B
| $1.48M | 8.4% |
39,000
-40,000
| -51% | -$865K |
|
2
Milestone Pharmaceuticals
MIST
$148M
| $1.32M | 7.48% |
658,553
+109,747
| +20% | +$193K |
|
|
3
Fennec Pharmaceuticals
FENC
$356M
| $1.15M | 6.54% |
123,000
-72,700
| -37% | -$629K |
|
|
4
Jasper Therapeutics
JSPR
$23.6M
| $949K | 5.39% |
398,558
+252,058
| +172% | +$764K |
|
|
AVDL
5
DELISTED
Avadel Pharmaceuticals
AVDL
| $912K | 5.18% |
59,700
-39,000
| -40% | -$507K |
|
|
6
Kiniksa Pharmaceuticals
KNSA
$4.87B
| $909K | 5.16% |
23,400
-22,500
| -49% | -$731K |
|
7
Insmed
INSM
$23.3B
| $900K | 5.11% |
6,250
-4,400
| -41% | -$539K |
|
|
8
Ardelyx
ARDX
$1.28B
| $897K | 5.09% |
162,750
-172,650
| -51% | -$938K |
|
9
Benitec Biopharma
BNTC
$393M
| $870K | 4.94% |
62,000
| – | – |
|
10
Syndax Pharmaceuticals
SNDX
$1.89B
| $846K | 4.81% |
55,000
| – | – |
|
|
11
Royalty Pharma
RPRX
$26.4B
| $755K | 4.29% |
+21,400
| New | +$775K |
|
12
Disc Medicine
IRON
$2.88B
| $700K | 3.98% |
10,600
| – | – |
|
|
13
BridgeBio Pharma
BBIO
$16.3B
| $691K | 3.92% |
13,300
-12,700
| -49% | -$619K |
|
14
Geron
GERN
$930M
| $685K | 3.89% |
500,000
| – | – |
|
15
Arcutis Biotherapeutics
ARQT
$3.44B
| $665K | 3.78% |
35,300
-11,000
| -24% | -$173K |
|
16
Regenxbio
RGNX
$659M
| $557K | 3.17% |
57,750
| – | – |
|
17
Seres Therapeutics
MCRB
$52.7M
| $522K | 2.97% |
27,138
+10,100
| +59% | +$161K |
|
|
18
MoonLake Immunotherapeutics
MLTX
$1.64B
| $484K | 2.75% |
+67,500
| New | +$3.52M |
|
|
19
Kura Oncology
KURA
$931M
| $407K | 2.31% |
+46,000
| New | +$328K |
|
20
Biohaven
BHVN
$2.22B
| $341K | 1.94% |
22,700
| – | – |
|
|
CMPS
21
Compass Pathways
CMPS
$1.59B
| $332K | 1.89% |
+58,000
| New | +$261K |
|
22
Praxis Precision Medicines
PRAX
$8.92B
| $302K | 1.72% |
+5,700
| New | +$276K |
|
|
DAWN
23
DELISTED
Day One Biopharmaceuticals
DAWN
| $296K | 1.68% |
+42,000
| New | +$289K |
|
24
Rocket Pharmaceuticals
RCKT
$360M
| $280K | 1.59% |
+86,000
| New | +$271K |
|
|
MRSN
25
DELISTED
Mersana Therapeutics
MRSN
| $200K | 1.14% |
25,760
| – | – |
|
Similar funds
PA
PA
SR
SCTC
SRA
CP
B
CVV
Lion Point Capital's Q3 2025 Portfolio in Review
As of Q3 2025, Lion Point Capital held 27 positions worth $17.6M, up 20% from $14.7M the previous quarter. Its ten largest holdings account for 58% of the portfolio.
Lion Point Capital deployed $1.84M of net new capital in Q3 2025, opening 8 new positions and adding to 3 existing holdings. Its largest new stake was MoonLake Immunotherapeutics: 67,500 shares worth $484K.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Ardelyx, an estimated $938K trimmed.
- Lion Point Capital's largest Q3 2025 buy was MoonLake Immunotherapeutics: 67,500 shares worth $484K.
- Lion Point Capital added most to Jasper Therapeutics in Q3 2025, an estimated $764K increase.
- Lion Point Capital's biggest Q3 2025 reduction was Ardelyx, cutting an estimated $938K.
- Lion Point Capital's ten largest holdings make up 58% of its $17.6M portfolio in Q3 2025.
- Lion Point Capital opened 8 new positions and closed 0 in Q3 2025.
- Lion Point Capital's portfolio value rose 20% quarter-over-quarter to $17.6M.
Based on Lion Point Capital's 13F filing for Q3 2025, filed 14 Nov 2025.